Back to Browse Journals » OncoTargets and Therapy » Volume 2

Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer

Authors Francesco Di Costanzo, Silvia Gasperoni, Virginia Rotella, Federica Di Costanzo

Published 7 July 2009 Volume 2009:2 Pages 179—188


Review by Single-blind

Peer reviewer comments 4

Francesco Di Costanzo,1 Silvia Gasperoni,1 Virginia Rotella,1 Federica Di Costanzo2

1Struttura Complessa Oncologia Medica, Azienda Ospedaliero Universitaria Careggi, Florence; 2Servizio di Oncologia: Ospedale S: Maria della Stella, Orvieto, Italy

Abstract: Taxanes are chemotherapeutic agents with a large spectrum of antitumor activity when used as monotherapy or in combination regimens. Paclitaxel and docetaxel have poor solubility and require a complex solvent system for their commercial formulation, Cremophor EL® (CrEL) and Tween 80® respectively. Both these biological surfactants have recently been implicated as contributing not only to the hypersensitivity reactions, but also to the degree of peripheral neurotoxicity and myelosuppression, and may antagonize the cytotoxicity. Nab-paclitaxel, or nanoparticle albumin-bound paclitaxel (ABI-007; Abraxane®), is a novel formulation of paclitaxel that does not employ the CrEL solvent system. Nab-paclitaxel demonstrates greater efficacy and a favorable safety profile compared with standard paclitaxel in patients with advanced disease (breast cancer, non-small cell lung cancer, melanoma, ovarian cancer). Clinical studies in breast cancer have shown that nab-paclitaxel is significantly more effective than standard paclitaxel in terms of overall objective response rate (ORR) and time to progression. Nab-paclitaxel in combination with gemcitabine, capecitabine or bevacizumab has been shown to be very active in patients with advanced breast cancer. An economic analysis showed that nab-paclitaxel would be an economically reasonable alternative to docetaxel or standard paclitaxel in metastatic breast cancer. Favorable tumor ORR and manageable toxicities have been reported for nab-paclitaxel as monotherapy or in combination treatment in advanced breast cancer.

Keywords: breast cancer, nab-paclitaxel, chemotherapy

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Natural history of histologically moderate cervical dysplasia in adolescent and young women

Piris S, Bravo V, Álvarez C, Muñoz-Hernando L, Lorenzo-Hernando E, Oliver R, Marqueta-Marques L, Seoane-Ruiz JM, Tejerizo-Garcia A, Jiménez JS

OncoTargets and Therapy 2014, 7:2101-2106

Published Date: 13 November 2014

A multidimensional risk factor model for suicide attempts in later life

Chan SMS, Chiu FKH, Lam CWL, Wong SMC, Conwell Y

Neuropsychiatric Disease and Treatment 2014, 10:1807-1817

Published Date: 18 September 2014

Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs

Accardo A, Aloj L, Aurilio M, Morelli G, Tesauro D

International Journal of Nanomedicine 2014, 9:1537-1557

Published Date: 27 March 2014

Profile of panobinostat and its potential for treatment in solid tumors: an update

Anne M, Sammartino D, Barginear MF, Budman D

OncoTargets and Therapy 2013, 6:1613-1624

Published Date: 15 November 2013

The impact of limbic system morphology on facial emotion recognition in bipolar I disorder and healthy controls

Bio DS, Soeiro-de-Souza MG, Otaduy MCG, Machado-Vieira R, Moreno RA

Neuropsychiatric Disease and Treatment 2013, 9:743-751

Published Date: 23 May 2013

Effects of repetitive transcranial magnetic stimulation on clinical, social, and cognitive performance in postpartum depression

Myczkowski ML, Dias AM, Luvisotto T, Arnaut D, Bellini BB, Mansur CG, Rennó J, Tortella G, Ribeiro PL, Marcolin MA

Neuropsychiatric Disease and Treatment 2012, 8:491-500

Published Date: 25 October 2012

Biocompatibility of chitosan-coated iron oxide nanoparticles with osteoblast cells

Shi S, Jia J, Guo X, Zhao Y, Chen D, Guo Y, Cheng T, Zhang X

International Journal of Nanomedicine 2012, 7:5593-5602

Published Date: 25 October 2012

Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch

Chen CH, Lin YL, Liu YK, He PJ, Lin CM, Chiu YH, Wu CJ, Cheng TL, Liu SJ, Liao KW

International Journal of Nanomedicine 2012, 7:607-621

Published Date: 3 February 2012

A new method for cancer detection based on diffusion reflection measurements of targeted gold nanorods

Ankri R, Peretz V, Motiei M, Popovtzer R, Fixler D

International Journal of Nanomedicine 2012, 7:449-455

Published Date: 31 January 2012

Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells

Xinying Wu, Yanbin Tan, Hui Mao, et al

International Journal of Nanomedicine 2010, 5:385-399

Published Date: 26 May 2010